Publications
Eckel J. Integrins-Mediators of cellular adhesion or more?. Acta Physiol (Oxf). 2020;229(3):e13482. doi: 10.1111/apha.13482
Valencia I, Perió C, Lorenzo Ó, Sánchez-Ferrer C, Eckel J, Ramacho T. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? Front. Pharmacol. 2020;11:1161. DOI: 10.3389/fphar.2020.01161
Romacho T, Sell H, Indrakusuma I, Roehrborn D, Castañeda TR, Jelenik T, Markgraf D, Hartwig S, Weiss J, Al-Hasani H, Roden M, Eckel J. DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity. Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E590-E599. DOI: 10.1152/ajpendo.00323.2019
Haahr H, Heise T. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clin Pharmacokinet. 2020 Feb;59(2):155-172. DOI: 10.1007/s40262-019-00834-5
Eckel J. Myokines in metabolic homeostasis and diabetes. Diabetologia. 2019 Sep;62(9):1523-1528. DOI: 10.1007/s00125-019-4927-9
Zaharia OP, Strassburger K, Strom A, Bönhof GJ, Karusheva Y, Antoniou S, Bódis K, Markgraf DF, Burkart V, Müssig K, Hwang JH, Asplund O, Groop L, Ahlqvist E, Seissler J, Nawroth P, Kopf S, Schmid SM, Stumvoll M, Pfeiffer AFH, Kabisch S, Tselmin S, Häring HU, Ziegler D, Kuss O, Szendroedi J, Roden M; German Diabetes Study Group. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694. DOI: 10.1016/S2213-8587(19)30187-1
Otter S, Lammert E. Exciting Times for Pancreatic Islets: Glutamate Signaling in Endocrine Cells. Trends Endocrinol Metab. 2016;27:177-88. DOI: 10.1016/j.tem.2015.12.004.
Marquard J, Stirban A, Schliess F, Sievers, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E. Effects of dextromethorphan as add‐on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo‐controlled, double‐blinded, multiple crossover, single‐dose clinical trial. Diabetes, Obesity and Metabolism. 2015;18(1):100-103. DOI: 10.1111/dom.12576
Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O, Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F, Rupnik MS, Heise T, Berggren PO, Klöcker N, Meissner T, Mayatepek E, Eberhard D, Kragl M, Lammert E. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nature Medicine. 2015;21:363-372. DOI: 10.1038/nm.3822
Abstracts
Eckel J, Hasse B, Belgardt BF, Hecht M, Wördenweber R, Piechot A, Roden M. OP 09 Novel agents in type 1 diabetes: 54 Development of novel modulators of the GABAA receptor for diabetes therapy. Diabetologia. 2020 Sept;63(Supplement 1):OP 09 Novel agents in type 1 diabetes. DOI: 10.1007/s00125-020-05221-5
Hasse B, Belgardt BF, Hecht M, Wördenweber R, Piechot A, Roden M, Eckel J. 1067-P: Developtment of Novel Modulators of the GABAA Receptor for Diabetes Therapy. Diabetes. 2020 Jun;69(Supplement 1):1067-P. DOI: 10.2337/db20-1067-P